Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Frequently asked questions
What sector does Evolus Inc (EVL) operate in?
Evolus Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Evolus Inc (EVL) current stock price?
As of the latest data, Evolus Inc stock price is €6.36, with a previous close of €6.20. Evolus Inc gained €0.16 in the last trading session, representing a 2.58% increase.
What is Evolus Inc (EVL) current market capitalization?
Evolus Inc market cap is approximately 420.21 million.
What is Evolus Inc (EVL) Earnings Per Share (EPS)?
The trailing EPS is -€0.45.
What is Evolus Inc (EVL) EBITDA?
Evolus Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.18 million.
Does Evolus Inc (EVL) pay dividends?
No. Evolus Inc does not pay a dividend.
When is Evolus Inc (EVL) next earnings report?
Evolus Inc is expected to release its next earnings report on September 30, 2026.
What is Evolus Inc (EVL) beta (volatility) score?
Evolus Inc has a beta of 1.340, suggesting it is more volatile than the market.